Why this fund manager is 'very happy' to own this ASX 200 share

The ASX 200 stock has come under some selling pressure in 2023, but this fundie sees better days ahead.

| More on:
A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 200 Index share CSL Ltd (ASX: CSL) is historically a long-term outperformer. But the stock has struggled in 2023.

Shares in the biotechnology company are currently trading for $266.80 apiece, down 5.3% since the opening bell of 3 January. That compares to a 3% gain posted by the ASX 200.

Here's why the ASX 200 share has come under pressure. And why this fund manager is "very happy" to own the biotech company.

What's happening with the ASX 200 share?

As you can see in the chart above, the CSL share price really hit some turbulence on 14 June.

That came after the ASX 200 share announced a downgrade of its FY 2023 profit guidance. This was driven by higher than initially forecast foreign currency headwinds.

At the time, CSL revised its forecast for its full-year net profits after tax and amortisation (NPATA) to the range of US$2.9 billion to US$3 billion in constant currency.

That revision saw the ASX 200 share close the day down 6.9%.

CSL reported its audited results on 15 August. And NPATA came in right near the bottom end of that forecast, at US$2.86 billion.

Other highlights of the FY 2023 results included a 31% increase in revenue in constant currency to US$13.31 billion. And the full-year dividend increased 6% to US$2.36 per share.

Management also reaffirmed its FY 2024 guidance. They expect NPATA of in the range of US$2.9 billion to US$3 billion in constant currency. And FY 2024 revenue growth of 9% to 11%.

Which brings us to Patrick Hodgens, managing director Firetrail Investments.

CSL counts amongst the biggest holdings at Firetrail Investments' high conviction fund.

And Hodgens wasn't put off by the ASX 200 share's results.

According to The Australian Financial Review, Firetrail believes this is a case of CEO Paul McKenzie "looking to reset".

According to Hodgens:

We're very happy to be owning CSL over the medium term and, in fact, we bought quite a bit more on the back of that perceived weakness by the market. We think CSL has some really good earnings upside if you look out two to three years.

CSL share price snapshot

As mentioned above, the CSL share price has underperformed in 2023 and over the past 12 months.

The ASX 200 share has outperformed longer-term, up 27% in five years.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

A male ASX investor sits cross-legged with a laptop computer in his lap with a slightly crazed, happy, excited look on his face while next to him a graphic of a rocket shoots upwards with graphics of stars scattered around it
Healthcare Shares

Up 10x since July, could this hot ASX stock be the next Droneshield?

Investors chase asymmetric upside and 4DMedical is one of the ASX's hottest stocks right now.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Is Medibank stock a buy for its 5.5% dividend yield?

This business is providing investors with very healthy dividends.

Read more »

A doctor shrugs and holds his hands out.
Healthcare Shares

Down 36% in 2025, should you buy CSL shares today?

A leading investment expert offers his outlook for CSL’s beaten-down share price.

Read more »

Three guys in shirts and ties give the thumbs down.
Healthcare Shares

Why did Macquarie just downgrade CSL shares?

The broker has taken an axe to its valuation of this biotech giant.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which drug company could pile on almost 30% in gains according to RBC Capital?

This drug company has plenty of irons in the fire, RBC Capital Markets says.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

This ASX 200 stock is charging higher on FDA approval news

This stock is avoiding the market weakness on Monday. Let's find out why.

Read more »